Journal of Child Neurology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Packer, R. J.
Right arrow Articles by Rosser, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Packer, R. J.
Right arrow Articles by Rosser, T.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Child Neurology, Vol. 17, No. 8, 638-641 (2002)
DOI: 10.1177/088307380201700816

Reviews

Review ArticLe : Therapy for Plexiform Neurofibromas in Children With Neurofibromatosis 1: An Overview

Roger J. Packer, MD

Department of Neurology and Pediatrics Center for Neuroscience and Behavioral Medicine, Children's National Medical Center, The George Washington University, Washington, DC

Tena Rosser, MD

Department of Neurology and Pediatrics Center for Neuroscience and Behavioral Medicine, Children's National Medical Center, The George Washington University, Washington, DC

Plexiform neurofibromas are one of the most common and disabling features of neurofibromatosis 1. Treatment options for patients with plexiform neurofibromas have been limited, with surgery being the primary option for patients with progressive lesions causing significant morbidity. Trials have evaluated other treatment approaches, including the use of antihistamines, maturation agents, and antiangiogenic agents. The design of such trials and entry criteria have been quite variable, and results have been difficult to interpret. As more is understood concerning the molecular genetic underpinnings of plexiform neurofibromas, new avenues of treatment are being explored. Evaluation of clinical trials is challenging because of the unpredictable nature of plexiform neurofibromas and difficulties in measuring objective responses. The use of innovative neuroimaging techniques and other outcome measures may greatly improve the design of trials and evaluation of potential effective agents. (J Child Neurol 2002;17:638-641).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 NeurologyHome page
D. Babovic-Vuksanovic, K. Ballman, V. Michels, P. McGrann, N. Lindor, B. King, J. Camp, V. Micic, N. Babovic, X. Carrero, et al.
Phase II trial of pirfenidone in adults with neurofibromatosis type 1
Neurology, November 28, 2006; 67(10): 1860 - 1862.
[Abstract] [Full Text] [PDF]